Pharmacological characterization of the selective 11β-hydroxysteroid dehydrogenase 1 inhibitor, BI 135585, a clinical candidate for the treatment of type 2 diabetes
Bradford S. Hamilton(Boehringer Ingelheim (Germany)), Gerard M. McGeehan, David A. Claremon, Joan Guo, Deepak S. Lala(Duke University Hospital), Yi Zhao(National University of Singapore), Paula M. Krosky, Frank Himmelsbach(Boehringer Ingelheim (Germany)), Annette Schuler‐Metz(Boehringer Ingelheim (Germany)), Shi Meng, Linghang Zhuang, Herbert Nar(Boehringer Ingelheim (Germany)), Rong Guo(Sun Yat-sen University)
Cited by 29
Related Papers
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion
|JAMA Oncology|2019|559
Crystal structure analysis of oxidized Pseudomonas aeruginosa azurin at pH 5·5 and pH 9·0
|Journal of Molecular Biology|1991|487
Structure-Based Design of Novel Potent Nonpeptide Thrombin Inhibitors
|Journal of Medicinal Chemistry|2002|454
Biophysics in drug discovery: impact, challenges and opportunities
|Nature Reviews Drug Discovery|2016|383